In a groundbreaking narrative review published by Burtscher et al., researchers delve into the crucial examination of dexamethasone, an anti-inflammatory corticosteroid, in the context of preventing altitude-related illnesses. Moving beyond the realms of basic pharmacology, the study focuses specifically on acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). These conditions pose significant health risks to individuals who rapidly ascend to high altitudes, whether for recreational purposes, military operations, or scientific exploration. The synthesis of available evidence sheds light on dexamethasone’s potential benefits and efficacy in mitigating these life-threatening conditions while concurrently addressing the impairment of performance often associated with rapid ascents to elevations above 2,500 meters.
Altitude sickness manifests due to the physiological stressors placed on the body caused by the lower oxygen levels present at high elevations. As individuals ascend, their bodies must acclimatize to the diminishing oxygen availability, which can lead to a plethora of symptoms encompassing headaches, dizziness, and nausea. In severe cases, this can escalate to confusion, loss of coordination, and even death. Recognizing the gravity of these potential health violations, this review emphasizes the importance of understanding preventive measures, particularly pharmacological interventions such as dexamethasone.
Dexamethasone functions primarily through its anti-inflammatory properties, exerting effects that can alter the body’s response to injury and inflammation. The relevance of inflammation in altitude sickness has garnered increasing attention; inflammation can exacerbate the symptoms connected to AMS, HACE, and HAPE. With this understanding, researchers have sought to explore how dexamethasone might limit the inflammatory responses that occur following rapid ascents and subsequently reduce the incidence and severity of altitude sickness.
One of the striking findings from the review indicates that dexamethasone could potentially act not just as a treatment for altitude sickness but also as a preventive measure. There is promising evidence that administration of the drug prior to ascending to high altitudes can mitigate the onset of AMS while also limiting more severe manifestations of altitude sickness like HACE and HAPE. This insight is particularly relevant for individuals such as military personnel or mountaineers, who often face time constraints and may not have the luxury of acclimatization opportunities.
Moreover, the review discusses the optimal dosing strategies for dexamethasone to maximize its protective effects against altitude sickness. Recommendations suggest that a regimen involving a short course of dexamethasone, initiated a few hours before ascent, balances efficacy with safety, minimizing potential side effects that can arise from corticosteroid use. This specificity in treatment regimens reflects a nuanced appreciation for the drug’s pharmacokinetics and its interaction with various physiological pathways critical during altitude exposure.
An essential facet of the review also incorporates the examination of dexamethasone in relation to athletic performance and cognitive function. High-altitude conditions can lead not only to physical fatigue but cognitive declines that impair decision-making and coordination. By mitigating the adverse impacts of altitude sickness, dexamethasone emerges as a promising agent that could enhance overall performance during critical moments of high-altitude exertion. Such findings prompt broader considerations about the applications of dexamethasone beyond medical contexts to athletic and high-stake environments.
Furthermore, the review contextualizes dexamethasone’s role within the broader landscape of altitude sickness treatments. As the research community continues to explore various pharmacological agents, dexamethasone stands out due to its robust profile and well-characterized mechanism of action. Comparative analyses with other potential treatments reveal that while alternatives exist, dexamethasone’s proactive approach in prevention, coupled with effects on both physical and cognitive performance, set it apart as a leading contender in altitude sickness management.
Despite the promising implications of dexamethasone, it is also critical to underscore potential limitations and side effects associated with corticosteroid use. Adverse effects can include gastrointestinal disturbances, increased susceptibility to infections, and mood changes, which necessitate careful consideration by healthcare professionals when prescribing the medication, particularly in otherwise healthy individuals ascending to high altitudes. This aspect of patient management remains vital, as balancing the benefits of preventive treatments against possible risks is fundamental in clinical practice.
The review concludes by calling for further research to solidify the foundations of use for dexamethasone in altitude sickness prevention. While the existing literature provides a robust starting point, a deeper understanding of individual variability, long-term effects, and broader impacts on different populations remains necessary. Experimental studies, randomized controlled trials, and real-world data collection can enhance clarity surrounding dosing regimens and long-term outcomes associated with dexamethasone use in altitude settings.
In the wake of the continuing exploration into high-altitude physiology, the authors advocate for an integrative approach combining pharmacological strategies, education on acclimatization techniques, and tailored guidelines for populations at risk of severe altitude sickness. This holistic view is critical for ensuring that individuals can engage safely in high-altitude activities, allowing for both an appreciation of the challenges posed by altitude and the innovative solutions available to address these issues effectively.
The research encapsulated in this narrative review not only offers hope for better management of altitude sickness through dexamethasone but also emphasizes the need for ongoing scientific inquiry into altitude-related health issues. As our understanding of the human body’s response to high-altitude environments continues to evolve, so too must our preventive strategies and treatments, paving the way for safer experiences for adventurers, athletes, and military personnel worldwide.
In conclusion, dexamethasone’s role in preventing altitude sickness represents a significant advancement in our approach to high-altitude health challenges. As research advances in this domain, it further strengthens the case for integrating pharmacological strategies with broader preventive measures. The quest to conquer altitude sickness, while harnessing the pharmacological advantages offered by drugs like dexamethasone, reflects the future of high-altitude medicine and performance optimization.
Subject of Research: Dexamethasone for prevention of altitude-related illnesses
Article Title: Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: a narrative review.
Article References:
Burtscher, J., Gatterer, H., Beidleman, B.A. et al. Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: a narrative review. Military Med Res 12, 48 (2025). https://doi.org/10.1186/s40779-025-00634-y
Image Credits: AI Generated
DOI: 10.1186/s40779-025-00634-y
Keywords: altitude sickness, dexamethasone, AMS, HACE, HAPE, high altitude, preventive measures, military personnel, cognitive function.
